Retrospective observational study to characterize and evaluate the clinical results of patients who received Benralizumab after its marketing approval in Spain. (ORB STUDY II)
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: ASTRAZENECA FARMACEUTICA ESPAÑA SA
- Execution start: 03/11/2020
- End of execution: 30/06/2021
- PI: FRANCISCO CASAS MALDONADO